News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
Market Access Buyer’s remorse: The UK’s VPAG With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.
News UK is becoming an 'outlier' for pharma, hitting investment UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
Market Access NHS medicines spending in England in greater focus Leela Barham provides a perspective on the ABPI blog that covers understanding NHS medicines spending in England.
News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.